Related Experiment Video

Updated: May 29, 2026

5/6th Nephrectomy in Combination with High Salt Diet and Nitric Oxide Synthase Inhibition to Induce Chronic Kidney Disease in the Lewis Rat
08:50

5/6th Nephrectomy in Combination with High Salt Diet and Nitric Oxide Synthase Inhibition to Induce Chronic Kidney Disease in the Lewis Rat

Published on: July 3, 2013

Ezetimibe alone or in combination with pitavastatin prevents kidney dysfunction in 5/6 nephrectomized rats fed

Yusaku Mori1, Tsutomu Hirano

  • 1Department of Diabetes, Metabolism, and Endocrinology, Showa University School of Medicine, Tokyo, Japan.

Metabolism: Clinical and Experimental
|August 27, 2011
PubMed

Insights

Ezetimibe protects kidneys by inhibiting cholesterol absorption and reducing oxidative stress in rats. Pitavastatin further improves kidney health by increasing nitric oxide production, with combined therapy showing synergistic benefits.

Area of Science:

  • Nephrology
  • Cardiovascular Pharmacology
  • Biochemistry

Background:

  • Chronic kidney disease (CKD) is a significant health concern associated with dyslipidemia.
  • Cholesterol metabolism plays a role in the progression of kidney damage.
  • Investigating therapeutic targets for renoprotection is crucial.

Purpose of the Study:

  • To investigate the renoprotective effects of ezetimibe, a cholesterol absorption inhibitor.
  • To determine the impact of ezetimibe and pitavastatin, alone and in combination, on kidney damage in a rat model.
  • To elucidate the relationship between cholesterol absorption, oxidative stress, and kidney injury.

Main Methods:

  • A 5/6 nephrectomized (Nx) rat model was used, fed a high-cholesterol diet.
  • Rats were treated with ezetimibe, pitavastatin, or a combination for 8 weeks.
  • Kidney pathology, endothelial nitric oxide synthase (eNOS) mRNA expression, and oxidative stress markers (8-hydroxy-2'-deoxyguanosine) were assessed.

Main Results:

  • Ezetimibe attenuated hypercholesterolemia, kidney dysfunction, and pathological damage, significantly associated with reduced oxidative stress (8-OHdG).
  • Pitavastatin suppressed kidney damage and upregulated eNOS mRNA, independent of cholesterol reduction.
  • Combination therapy demonstrated synergistic renoprotective effects, with kidney damage linked to cholesterol absorption markers.

Conclusions:

  • Ezetimibe confers renoprotection by inhibiting cholesterol absorption and reducing oxidative stress.
  • Pitavastatin offers additive renoprotection through mechanisms independent of cholesterol reduction, likely involving nitric oxide.
  • Cholesterol absorption markers are independently associated with kidney damage, highlighting their therapeutic relevance.

More Related Videos

LDL Cholesterol Uptake Assay Using Live Cell Imaging Analysis with Cell Health Monitoring08:45

LDL Cholesterol Uptake Assay Using Live Cell Imaging Analysis with Cell Health Monitoring

Published on: November 17, 2018

Related Concept Videos

Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
Antihypertensive Drugs: Direct Renin Inhibitors01:25

Antihypertensive Drugs: Direct Renin Inhibitors

The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
Chronic Kidney Disease III: Interprofessional Care01:28

Chronic Kidney Disease III: Interprofessional Care

Chronic kidney disease (CKD) requires collaborative and comprehensive management. CKD progresses through stages and can lead to end-stage kidney disease (ESKD) if untreated. Interprofessional collaboration and patient education are crucial, enabling patients to manage their health and improve their quality of life.Diagnostic approach for chronic kidney diseaseThe diagnosis of CKD primarily focuses on the glomerular filtration rate (GFR), which assesses kidney function by measuring how well...
Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors01:30

Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors

Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
Cholesterol: Significance and Regulation01:29

Cholesterol: Significance and Regulation

Although not a source of energy, cholesterol plays a significant role as a foundational structure for bile salts, steroid hormones, and vitamin D, as well as being a crucial component of plasma membranes. Approximately 15% of blood cholesterol is derived from our diet, with the remainder synthesized from acetyl CoA by the liver and intestines. Cholesterol is eliminated from the body through its conversion into bile salts, which are eventually discarded in the feces.
Considering cholesterol and...
Renal Drug Excretion: Tubular Secretion01:28

Renal Drug Excretion: Tubular Secretion

Active tubular secretion is a robust, energy-demanding process that utilizes carrier systems to transport drugs into renal tubules. The active renal secretion systems include the organic anion transporter (OAT) for weak acids and the organic cation transporter (OCT) for weak bases. Structurally similar drugs can compete for the same transporter, potentially leading to drug accumulation and toxicity. However, this principle can be exploited therapeutically. One example is probenecid (Probalan),...